On Halloween, Lexicon was haunted again as an FDA advisory committee voted 11-3 to reject Zynquista as an accompanying ...

Lexicon Pharmaceuticals shares have been halted all day as a Food and Drug Administration advisory committee was scheduled to vote on Zynquista as an adjunct to insulin therapy for glycemic control in ...

Committee members said there was uncertainty around sotagliflozin in patients with kidney disease. The FDA is currently ...

Lexicon did manage to get approval for type 1 diabetes in Europe, but the product was never launched there for commercial ...

Lexicon Pharmaceuticals received a negative vote from a Food and Drug Administration advisory committee for Zynquista as an adjunct to insulin therapy for glycemic control in adults with Type 1 ...

FDA staff raised familiar safety concerns about sotagliflozin as a treatment for type 1 diabetes (T1D) as the agency again ...

Off-label SGLT2 inhibitors increase the risk of euglycemic diabetic ketoacidosis. GLP-1RAs may lead to rapid weight loss in ...

A collaboration of researchers led by Emory University Rollins School of Public Health, Atlanta, is urging caution when ...

Lexicon currently sells the drug under the brand name Inpefa to reduce the risk of cardiovascular complications among patients with heart failure ... the threat of diabetic ketoacidosis, which ...